Gardasil® - The new HPV vaccine: The right product, the right time? A commentary

Joel Lexchin, Neil Arya, Sonal Singh

Research output: Contribution to journalReview article

Abstract

The federal and provincial governments have undertaken a universal immunization program to protect school-aged girls against cervical cancer using the new human papillomavirus vaccine Gardasil®. While the vaccine appears to be effective and safe, there are a number of important unanswered questions regarding it and the effects of the immunization program. Here we briefly review key literature about the vaccine and then use the Erickson criteria, which offer an evidence basis for decision-making regarding national immunization strategies, to evaluate whether the program is congruent with sound public health policy. Our analysis of the national decision to recommend and fund a vaccination program using Gardasil® raises significant questions about the basis for this program.

Original languageEnglish (US)
Pages (from-to)26-36
Number of pages11
JournalHealthcare Policy
Volume5
Issue number4
DOIs
StatePublished - May 2010
Externally publishedYes

ASJC Scopus subject areas

  • Health Policy
  • Public Health, Environmental and Occupational Health

Fingerprint Dive into the research topics of 'Gardasil® - The new HPV vaccine: The right product, the right time? A commentary'. Together they form a unique fingerprint.

  • Cite this